TheraRadar
← Back
Data updated: Jun 28, 2026

RELIANT HOLDINGS LTD

Pharma
Pharmaceuticals

RELIANT HOLDINGS LTD is a pharmaceutical company with 1 FDA-approved products.

2014
Since
1
Drugs
-
Trials
6
New Drugs (2yr)
Modality:
1 Small Molecules

Upcoming FDA Decisions

Full Calendar →
Jan 20, 2027 — Foundayo (orforglipron)

RELIANT HOLDINGS LTD's Key Drugs

RELIANT HOLDINGS LTD's core commercial portfolio centers on CARBON DIOXIDE, USP — its most strategically important drugs approved in the last 15 years.

CARBON DIOXIDE, USP
Respiratory
Approved 2013

RELIANT HOLDINGS LTD's Recent FDA Approvals

RELIANT HOLDINGS LTD secured 6 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

CARBON DIOXIDE, USP NDA
2025-10-25
carbon dioxide
CARBON DIOXIDE, USP NDA
2025-06-16
carbon dioxide
CARBON DIOXIDE, USP NDA
2025-04-21
carbon dioxide
Carbon Dioxide, USP NDA
2025-02-02
carbon dioxide
Carbon Dioxide, USP NDA
2024-11-09
carbon dioxide, usp
CARBON DIOXIDE, USP NDA
2024-08-10
carbon dioxide

RELIANT HOLDINGS LTD's Therapeutic Areas

Disease areas where RELIANT HOLDINGS LTD has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

RELIANT HOLDINGS LTD Pipeline Snapshot

Active clinical trials for RELIANT HOLDINGS LTD across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • CARBON DIOXIDE, USP leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling